JP5677972B2 - ヒト血清アルブミンリンカーおよびそのコンジュゲート - Google Patents

ヒト血清アルブミンリンカーおよびそのコンジュゲート Download PDF

Info

Publication number
JP5677972B2
JP5677972B2 JP2011536365A JP2011536365A JP5677972B2 JP 5677972 B2 JP5677972 B2 JP 5677972B2 JP 2011536365 A JP2011536365 A JP 2011536365A JP 2011536365 A JP2011536365 A JP 2011536365A JP 5677972 B2 JP5677972 B2 JP 5677972B2
Authority
JP
Japan
Prior art keywords
hsa linker
hsa
cancer
binding
trastuzumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011536365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509259A (ja
JP2012509259A5 (enExample
Inventor
シャーロット マクドナー
シャーロット マクドナー
マイケル フェルダウス
マイケル フェルダウス
アレクサンドラ フハロブ
アレクサンドラ フハロブ
Original Assignee
メリマック ファーマシューティカルズ インコーポレーティッド
メリマック ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/040259 external-priority patent/WO2009126920A2/en
Application filed by メリマック ファーマシューティカルズ インコーポレーティッド, メリマック ファーマシューティカルズ インコーポレーティッド filed Critical メリマック ファーマシューティカルズ インコーポレーティッド
Publication of JP2012509259A publication Critical patent/JP2012509259A/ja
Publication of JP2012509259A5 publication Critical patent/JP2012509259A5/ja
Application granted granted Critical
Publication of JP5677972B2 publication Critical patent/JP5677972B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011536365A 2008-11-18 2009-10-14 ヒト血清アルブミンリンカーおよびそのコンジュゲート Expired - Fee Related JP5677972B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11579708P 2008-11-18 2008-11-18
US61/115,797 2008-11-18
PCT/US2009/040259 WO2009126920A2 (en) 2008-04-11 2009-04-10 Human serum albumin linkers and conjugates thereof
USPCT/US2009/040259 2009-04-10
PCT/US2009/060721 WO2010059315A1 (en) 2008-11-18 2009-10-14 Human serum albumin linkers and conjugates thereof

Publications (3)

Publication Number Publication Date
JP2012509259A JP2012509259A (ja) 2012-04-19
JP2012509259A5 JP2012509259A5 (enExample) 2013-05-23
JP5677972B2 true JP5677972B2 (ja) 2015-02-25

Family

ID=42198443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536365A Expired - Fee Related JP5677972B2 (ja) 2008-11-18 2009-10-14 ヒト血清アルブミンリンカーおよびそのコンジュゲート

Country Status (6)

Country Link
US (4) US8927694B2 (enExample)
JP (1) JP5677972B2 (enExample)
KR (1) KR20110112301A (enExample)
CN (1) CN102282168A (enExample)
BR (1) BRPI0921586A2 (enExample)
WO (1) WO2010059315A1 (enExample)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US8580263B2 (en) * 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ， エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
MX2012002014A (es) 2009-08-17 2012-06-13 Roche Glycart Ag Inmunoconjugados dirigidos.
BR112012009450A2 (pt) * 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
CA2789337A1 (en) 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
US8877687B2 (en) 2010-04-26 2014-11-04 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
EA201291180A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
CN103327983A (zh) 2010-12-06 2013-09-25 梅里麦克制药股份有限公司 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药
CA2822938A1 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
WO2012116317A2 (en) * 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
AU2012229147B2 (en) * 2011-03-11 2015-12-24 Merrimack Pharmaceuticals, Inc. Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
US20150231238A1 (en) 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
AU2012251583B2 (en) 2011-05-05 2017-06-08 Albumedix Ltd. Albumin variants
EP2760892A1 (en) 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
SG11201401717VA (en) * 2011-11-04 2014-05-29 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013096939A1 (en) * 2011-12-23 2013-06-27 Sri International Selective binding compounds
WO2013096940A1 (en) * 2011-12-23 2013-06-27 Sri International Double binding constructs
SG11201404007WA (en) 2012-01-13 2014-08-28 Apo T B V Aberrant cell-restricted immunoglobulins provided with a toxic moiety
US20150011736A1 (en) * 2012-01-20 2015-01-08 Sea Lane Biotechnologies, Llc Binding molecule conjugates
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
CA2873111A1 (en) * 2012-05-11 2013-11-14 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
JP6498601B2 (ja) 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014089127A1 (en) 2012-12-03 2014-06-12 Merrimack Pharmaceuticals, Inc. Combination therapy for treating her2-positive cancers
WO2014098464A1 (ko) * 2012-12-18 2014-06-26 이화여자대학교 산학협력단 인간혈청알부민 열안정화용 조성물 및 이를 이용한 열안정화된 인간혈청알부민의 제조방법
US9962452B2 (en) * 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2016520586A (ja) 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
MY176175A (en) 2013-05-13 2020-07-24 Vision Global Holdings Ltd Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
US20160114057A1 (en) * 2013-05-24 2016-04-28 Zyeworks Inc. Modular protein drug conjugate therapeutic
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
US20150147326A1 (en) 2013-09-30 2015-05-28 Daiichi Sankyo Company, Limited Protein biomarker and uses thereof
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
DK3424955T3 (da) 2013-12-25 2025-06-16 Daiichi Sankyo Co Ltd Fremgangsmåde til fremstilling af anti-trop2 antistof-lægemiddelkonjugat
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10487140B2 (en) 2014-01-14 2019-11-26 Integrated Biotherapeutics, Inc. Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
EP4212552B1 (en) 2014-01-31 2024-11-13 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
HRP20250041T1 (hr) 2014-02-28 2025-03-14 Merus N.V. Antitijelo koje veže erbb-2 i erbb-3
ES2900898T3 (es) 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Anticuerpos biespecíficos inmunoactivadores
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
US11473080B2 (en) * 2014-04-30 2022-10-18 The Board Of Trustees Of The University Of Illinois Method for generating high affinity, bivalent binding agents for sandwich assays
CA2947157A1 (en) 2014-05-13 2015-11-19 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
CA2944892A1 (en) * 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
US20160045596A1 (en) 2014-08-05 2016-02-18 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
WO2016070045A1 (en) * 2014-10-31 2016-05-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tlr9 targeted cytotoxic agents
UA120286C2 (uk) 2015-01-08 2019-11-11 Ґенмаб А/С Біспецифічне антитіло проти cd3 і cd20
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
AU2016293073B2 (en) 2015-07-15 2022-12-22 Genmab A/S Humanized or chimeric CD3 antibodies
AU2016305703B2 (en) * 2015-08-11 2019-07-25 Coherent Biopharma I, Limited Multi-ligand drug conjugates and uses thereof
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
IL257149B2 (en) 2015-08-21 2024-11-01 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
CA2999756A1 (en) * 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
KR20250157457A (ko) 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
KR101746152B1 (ko) 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
CN108431204A (zh) 2015-12-22 2018-08-21 阿尔布梅迪克斯医疗有限公司 改良的表达蛋白质的菌株
WO2017161173A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
CA3030636A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
WO2018162749A1 (en) 2017-03-09 2018-09-13 Genmab A/S Antibodies against pd-l1
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
TW202542161A (zh) 2017-05-15 2025-11-01 日商第一三共股份有限公司 抗體－藥物結合物及其用途
CN111148764B (zh) 2017-05-17 2025-08-12 美勒斯公司 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合
CA3064037A1 (en) 2017-06-20 2018-12-27 Albumedix Ltd Improved protein expression strains
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
PL3665198T3 (pl) 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
WO2019096226A1 (en) * 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
EP3831853A4 (en) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
KR20250172902A (ko) 2018-07-31 2025-12-09 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료
CA3113409A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
MA54139A (fr) 2018-11-06 2021-09-15 BioNTech SE Formulation d'anticorps
CN109627337B (zh) * 2018-12-29 2023-07-21 上海复宏汉霖生物技术股份有限公司 一种抗prlr的单克隆抗体及其制备方法和应用
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
CA3128148A1 (en) 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
CN111603567B (zh) * 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
US20220152204A1 (en) * 2019-03-26 2022-05-19 Shimadzu Corporation Photoimmunotherapy and pharmaceutical agent used therefor
WO2020237305A1 (en) * 2019-05-27 2020-12-03 Baker Heart and Diabetes Institute Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
US20230000774A1 (en) 2019-12-04 2023-01-05 Albumedix Limited Methods and compositions produced thereby
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
PL3865155T3 (pl) * 2020-02-13 2023-01-30 Orano Med Sposób miejscowo-specyficznego modyfikowania przeciwciała
CA3168613A1 (en) 2020-03-18 2021-09-23 Genmab A/S Antibodies binding to b7h4
US20230293647A1 (en) 2020-04-09 2023-09-21 Autolus Limited Polypeptide
CA3176436A1 (en) 2020-05-08 2021-11-11 Tahamtan Ahmadi Bispecific antibodies against cd3 and cd20
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
JP2023532807A (ja) 2020-07-08 2023-07-31 ラヴァ・セラピューティクス・エヌ・ヴイ Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
CN116194477A (zh) 2020-08-06 2023-05-30 生物技术欧洲股份公司 冠状病毒s蛋白的结合剂
JP2023541858A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023005435A (es) * 2020-11-10 2023-08-08 Univ New York Conjugados de monocuerpo-farmaco selectivos de macropinocitosis.
EP4259660A1 (en) 2020-12-10 2023-10-18 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
US20240141071A1 (en) 2021-02-26 2024-05-02 LAVA Therapeutics N.V. Antibodies that bind cd123 and gamma-delta t cell receptors
EP4334359A1 (en) 2021-05-07 2024-03-13 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
EP4363439A4 (en) * 2021-06-30 2025-12-17 Silver Creek Pharmaceuticals Inc Chimeric proteins for the targeted release of growth factors to the glomerulus
US20240409634A1 (en) 2021-09-13 2024-12-12 Janssen Biotech, Inc. CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
US11814437B2 (en) 2021-10-08 2023-11-14 Genmab A/S Antibodies binding to CD30 and CD3
EP4419109A1 (en) 2021-10-21 2024-08-28 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
KR20240101682A9 (ko) 2021-11-15 2025-12-10 시스트이뮨, 인코포레이티드 이중특이 항체-캄프토테신 약물 접합체 및 이의 약학적 용도
JP2024546948A (ja) * 2021-12-15 2024-12-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド コンジュゲート、それらの組成物、及びそれらの関連する方法
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
US12351650B2 (en) 2023-06-30 2025-07-08 Genmab A/S Antibodies binding to fibroblast activation protein alpha and death receptor 4
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025024780A1 (en) 2023-07-27 2025-01-30 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025040000A1 (zh) * 2023-08-18 2025-02-27 上海美雅珂生物技术有限责任公司 5t4抗体药物偶联物及其应用
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025158071A1 (en) 2024-01-26 2025-07-31 Sartorius Albumedix Limited Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction
CN118955647A (zh) * 2024-07-31 2024-11-15 西安交通大学医学院第一附属医院 Mdm2/mdmx抑制肽、组合物及制备方法与应用
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
EP4703468A1 (en) 2024-08-29 2026-03-04 Sartorius Albumedix Limited Methods and uses

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6009A (en) * 1849-01-09 Improvement in machines for gathering pea-vines
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4450103A (en) 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5753627A (en) 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
DK0573551T3 (da) 1991-02-27 2003-08-04 Micromet Ag Serinrige peptidlinkere
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
FR2686620B1 (fr) 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
CN1074243A (zh) 1993-02-06 1993-07-14 北京中化生物技术研究所 白介素6-白介素2融合蛋白及其制法和用途
US5780594A (en) 1993-03-01 1998-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Biologically active protein fragments containing specific binding regions of serum albumin or related proteins
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5733782A (en) 1993-10-25 1998-03-31 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
ATE483733T1 (de) 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
PE99498A1 (es) 1996-07-26 1999-01-21 Novartis Ag Polipeptidos de fusion
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US6191269B1 (en) 1997-05-30 2001-02-20 The Regents Of The University Of California Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
ATE249421T1 (de) 1997-06-23 2003-09-15 Tanabe Seiyaku Co Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
US6171809B1 (en) 1998-01-29 2001-01-09 Packard Instrument Company Method and compositions for detecting luciferase biological samples
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
ATE256659T1 (de) 1998-05-28 2004-01-15 Biogen Inc Ein vla-4-inhibitor: omepupa-v
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
US6355678B1 (en) 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
JP3180906B2 (ja) 1998-11-12 2001-07-03 日本電気株式会社 磁気抵抗効果型複合ヘッドの製造方法
DE60014588T2 (de) 1999-02-18 2006-02-23 F. Hoffmann-La Roche Ag Thioamidderivate
US8236159B2 (en) * 1999-04-13 2012-08-07 Applied Materials Inc. Electrolytic process using cation permeable barrier
US6265572B1 (en) 1999-04-20 2001-07-24 Hoffmann-La Roche Inc. Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
EP1741428A3 (en) 1999-08-13 2007-05-09 Biogen Idec MA, Inc. Cell adhesion inhibitors
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
WO2001036376A1 (en) 1999-11-18 2001-05-25 Ajinomoto Co., Inc. Novel phenylalanine derivatives
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
PL357109A1 (en) 1999-12-28 2004-07-12 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
WO2001070670A1 (en) 2000-03-23 2001-09-27 Ajinomoto Co., Inc. Novel phenylalanine derivative
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU6173501A (en) 2000-05-19 2001-12-03 Blood Res Center Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
US6787636B1 (en) 2000-07-14 2004-09-07 New Century Pharmaceuticals, Inc. Modified serum albumin with reduced affinity for nickel and copper
US20040247565A1 (en) 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US7015216B2 (en) 2000-07-21 2006-03-21 Elan Pharmaceuticals, Inc. Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors
US6689781B2 (en) 2000-07-21 2004-02-10 Elan Pharmaceuticals, Inc. Phenylalanine derivatives as alpha 4 integrin inhibitors
CN1325480C (zh) 2000-08-18 2007-07-11 味之素株式会社 苯基丙氨酸衍生物
JPWO2002022563A1 (ja) 2000-09-14 2004-01-22 東レ株式会社 ウレア誘導体及びそれを有効成分とする接着分子阻害剤
AU8811401A (en) 2000-09-25 2002-04-02 Toray Industries Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
DK1370531T3 (da) 2001-02-22 2007-06-25 Celltech R&D Ltd Phenylalaninenamidderivater der besidder en cyclobutengruppe, til anvendelse som integrininhibitorer
ES2180416B1 (es) 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
WO2003010135A1 (en) 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Novel phenylpropionic acid derivatives
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20030166559A1 (en) 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US20060241132A1 (en) 2002-03-22 2006-10-26 Toray Industries, Inc. A Corporation Of Japan Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
GB0216571D0 (en) 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
GB0216568D0 (en) 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
US7446125B2 (en) 2003-04-09 2008-11-04 Universidad Del Pais Vasco Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders
WO2005035719A2 (en) 2003-10-03 2005-04-21 Board Of Control Of Michigan Technological University Modified luciferase
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
JP2007536254A (ja) 2004-05-05 2007-12-13 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
TW200610754A (en) 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
US20060018859A1 (en) 2004-07-16 2006-01-26 Carter Daniel C Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
ZA200703478B (en) 2004-10-05 2008-07-30 Genentech Inc Therapeutic agents with decreased toxicity
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
EP1853309A4 (en) 2005-02-23 2008-10-22 Merrimack Pharmaceuticals Inc BISPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY
US20070243163A1 (en) 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
AU2007294805A1 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
US8580263B2 (en) 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
WO2008076949A2 (en) 2006-12-15 2008-06-26 Concert Pharmaceuticals Inc. Quinazoline derivatives and methods of treatment
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
KR20110044905A (ko) * 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
JP6200806B2 (ja) * 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
SG11201401717VA (en) * 2011-11-04 2014-05-29 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
US20150202287A1 (en) * 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents

Also Published As

Publication number Publication date
KR20110112301A (ko) 2011-10-12
JP2012509259A (ja) 2012-04-19
BRPI0921586A2 (pt) 2019-09-24
WO2010059315A1 (en) 2010-05-27
US20170204192A1 (en) 2017-07-20
US20150191545A1 (en) 2015-07-09
CN102282168A (zh) 2011-12-14
US20110059076A1 (en) 2011-03-10
US20120003221A1 (en) 2012-01-05
US8927694B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
JP5677972B2 (ja) ヒト血清アルブミンリンカーおよびそのコンジュゲート
JP5863926B2 (ja) ヒト血清アルブミンリンカーおよびそのコンジュゲート
US20250066494A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
JP5068270B2 (ja) 癌を処置するためのｉｌ−１７アンタゴニスト抗体
CN107849142B (zh) 拮抗性抗肿瘤坏死因子受体超家族抗体
US20230295326A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
CN109476745B (zh) 拮抗性抗肿瘤坏死因子受体超家族抗体
JP2024078461A (ja) Ｄｌｌ３結合タンパク質および使用方法
JP2024523003A (ja) Ｄｌｌ３標的化三重特異性タンパク質およびそれらの使用方法
JP2024520727A (ja) Ｂｃｍａ標的化三重特異性タンパク質およびその使用
US20240101693A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
HK1155491A (en) Human serum albumin linkers and conjugates thereof
HK1164903A (en) Human serum albumin linkers and conjugates thereof
WO2025122817A1 (en) Antagonistic cd40 antibodies
HK1253012B (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140313

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150105

R150 Certificate of patent or registration of utility model

Ref document number: 5677972

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees